{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:25Z","timestamp":1792516045160,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jacc.2017.08.037","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T16:15:46Z","timestamp":1506356146000},"page":"1760-1776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"title":["Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis"],"prefix":"10.1016","volume":"70","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.08.037_bib1","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1538-7836.2005.01380.x","article-title":"Determinants of the interindividual variability in response to antiplatelet drugs","volume":"3","author":"Rocca","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib10","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11886-011-0206-1","article-title":"Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance","volume":"13","author":"Hulot","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2017.08.037_bib13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejphar.2015.05.046","article-title":"In\u00a0vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist","volume":"762","author":"Hawes","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2017.08.037_bib15","doi-asserted-by":"crossref","first-page":"16830","DOI":"10.1073\/pnas.1406997111","article-title":"Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs","volume":"111","author":"Li","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2017.08.037_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib18","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.08.037_bib20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib21","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1160\/TH16-07-0557","volume":"117","author":"Sibbing","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/bja\/aew189","article-title":"Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study","volume":"117","author":"Malm","year":"2016","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jacc.2017.08.037_bib25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2017.08.037_bib27","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib28","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2017.08.037_bib29","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib31","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib34","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib35","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/eurheartj\/eht058","article-title":"Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?","volume":"34","author":"Patrono","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archinte.164.1.40","article-title":"Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses","volume":"164","author":"Hennekens","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib37","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(08)60691-1","article-title":"Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis","volume":"371","author":"Pickett","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib38","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.08.037_bib39","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib40","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib41","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib42","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib43","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000145171.89690.B4","article-title":"Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes","volume":"110","author":"Collet","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib44","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A\u00a0systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib45","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib47","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.jacc.2017.08.037_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cct.2013.09.014","article-title":"Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial","volume":"36","year":"2013","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacc.2017.08.037_bib51","unstructured":"Bayer HealthCare. Aspirin to Reduce Risk of\u00a0Initial Vascular Events (ARRIVE). Available at:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00501059. Accessed August 19, 2016."},{"key":"10.1016\/j.jacc.2017.08.037_bib52","unstructured":"British Heart Foundation. A Study of Cardiovascular Events in Diabetes (ASCEND) Trial Website. Available at: http:\/\/www.ctsu.ox.ac.uk\/ascend. Accessed August 13,\u00a02017."},{"key":"10.1016\/j.jacc.2017.08.037_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jacc.2017.08.037_bib55","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2017.08.037_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib58","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A\u00a0critical appraisal of aspirin in secondary prevention: is less more?","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":"A\u00a0randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents","volume":"101","author":"M\u00fcller","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib62","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib63","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib64","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib65","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib66","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib67","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A\u00a0comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib68","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib69","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib71","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2017.08.037_bib72","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib73","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib74","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","article-title":"Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 Trial","volume":"1","author":"Bonaca","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib76","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib77","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib80","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib81","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib82","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib83","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1160\/TH15-04-0355","article-title":"Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review","volume":"115","author":"Vries","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib85","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib86","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A\u00a0risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib87","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2017.08.037_bib88","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.jacc.2011.08.006","volume":"58","author":"Levine","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib89","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy","volume":"4","author":"Costa","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2017.08.037_bib90","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.037_bib91","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.01.102","article-title":"The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting","volume":"207","author":"Choi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib92","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","author":"Siller-Matula","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib93","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/CIRCULATIONAHA.116.023835","article-title":"Choices for potent platelet inhibition in patients with diabetes mellitus","volume":"134","author":"Storey","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib94","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2016.04.056","article-title":"Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy","volume":"68","author":"Stratz","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib95","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2017.08.037_bib96","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","article-title":"Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy","volume":"55","author":"Angiolillo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib97","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib98","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib99","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2012.08.964","article-title":"Reduction in platelet reactivity with prasugrel 5\u00a0mg in low-body-weight patients is noninferior to prasugrel 10\u00a0mg in higher-body-weight patients: results from the FEATHER trial","volume":"60","author":"Erlinge","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib100","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib101","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib102","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: A substudy from the prospective randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2017.08.037_bib103","article-title":"Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes","author":"Zeymer","year":"2016","journal-title":"Eur Heart J Acute Cardiovascular Care"},{"key":"10.1016\/j.jacc.2017.08.037_bib104","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/bja\/aev164","article-title":"Aspirin and coronary artery surgery: a systematic review and meta-analysis","volume":"115","author":"Hastings","year":"2015","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jacc.2017.08.037_bib105","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/eurheartj\/ehu158","article-title":"Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery","volume":"35","author":"Sousa-Uva","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib106","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.037_bib107","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.037_bib108","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.jacc.2016.09.967","article-title":"Risk associated with surgery within 12\u00a0months after coronary drug-eluting stent implantation","volume":"68","author":"Egholm","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.037_bib109","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/SLA.0000000000001246","article-title":"The Incremental risk of coronary stents on postoperative adverse events: a matched cohort study","volume":"263","author":"Holcomb","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacc.2017.08.037_bib110","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1538-7836.2011.04456.x","article-title":"Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery","volume":"9","author":"Savonitto","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.08.037_bib111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717393452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717393452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:14:25Z","timestamp":1760015665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717393452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":111,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0735109717393452"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.08.037","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}